ILLINOIS RETINA ASSOCIATES
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1976-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 3:1
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 4
2 (66.7%)Phase 3
1 (33.3%)Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections
Phase 3
Completed
- Conditions
- Pain
- Interventions
- Drug: 3.5% viscous lidocaine gel
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2010-05-04
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 120
- Registration Number
- NCT01027611
- Locations
- 🇺🇸
Illinois Retina Associates, Joliet, Illinois, United States
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 22
- Registration Number
- NCT00690313
- Locations
- 🇺🇸
Illinois Retina Associates, Harvey, Illinois, United States
Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
Phase 4
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 10
- Registration Number
- NCT00680498
- Locations
- 🇺🇸
Illinois Retina Associates, Oak Park, Illinois, United States
News
Pykus Therapeutics Completes Enrollment for Novel Retinal Detachment Treatment Trial
Pykus Therapeutics has completed enrollment for its PYK-2101 pilot study in Australia, testing a first-in-class biodegradable retinal hydrogel sealant for retinal detachment surgery.